Targretin(bexarotene)
Targretin (bexarotene) is a small molecule pharmaceutical. Bexarotene was first approved as Targretin on 1999-12-29. It is used to treat t-cell lymphoma cutaneous in the USA. It has been approved in Europe to treat t-cell lymphoma cutaneous. The pharmaceutical is active against retinoic acid receptor RXR-alpha, retinoic acid receptor RXR-gamma, and retinoic acid receptor RXR-beta. In addition, it is known to target peroxisome proliferator-activated receptor gamma.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Targretin (generic drugs available since 2014-08-12)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| bexarotene | ANDA | 2022-12-30 |
| targretin | New Drug Application | 2020-04-30 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
42 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | C85.9 | 2 | 4 | 1 | — | — | 7 | |
| Non-small-cell lung carcinoma | D002289 | 1 | 2 | 2 | — | 1 | 5 | ||
| Mycosis fungoides | D009182 | C84.0 | 1 | 1 | 1 | — | — | 3 | |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | 3 | — | — | 3 |
| Primary cutaneous anaplastic large cell lymphoma | D054446 | C86.6 | 1 | — | 1 | — | — | 2 | |
| Psychotic disorders | D011618 | F20.81 | — | — | 1 | — | — | 1 | |
| Cognition | D003071 | EFO_0003925 | — | — | 1 | — | — | 1 | |
| Alopecia areata | D000506 | EFO_0004192 | L63 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lung neoplasms | D008175 | C34.90 | 1 | 3 | — | — | — | 3 | |
| Myeloid leukemia acute | D015470 | C92.0 | 2 | 1 | — | — | — | 3 | |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | 1 | 1 | — | — | — | 2 |
| Sezary syndrome | D012751 | C84.1 | 1 | 1 | — | — | — | 2 | |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 1 | — | — | — | 2 |
| Pituitary acth hypersecretion | D047748 | EFO_1001110 | E24.0 | 1 | 1 | — | — | — | 1 |
| Leukemia | D007938 | C95 | — | 1 | — | — | — | 1 | |
| Myelodysplastic syndromes | D009190 | D46 | — | 1 | — | — | — | 1 | |
| Myelodysplastic-myeloproliferative diseases | D054437 | — | 1 | — | — | — | 1 | ||
| Parapsoriasis | D010267 | L41 | — | 1 | — | — | — | 1 |
Show 3 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Triple negative breast neoplasms | D064726 | 1 | — | — | — | — | 1 | ||
| Ductal carcinoma breast | D018270 | 1 | — | — | — | — | 1 | ||
| Invasive hydatidiform mole | D002820 | D39.2 | 1 | — | — | — | — | 1 | |
| Phenylketonurias | D010661 | E70.0 | 1 | — | — | — | — | 1 | |
| Neoplasms | D009369 | C80 | 1 | — | — | — | — | 1 | |
| Multiple myeloma | D009101 | C90.0 | 1 | — | — | — | — | 1 | |
| Thyroid neoplasms | D013964 | EFO_0003841 | 1 | — | — | — | — | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | BEXAROTENE |
| INN | bexarotene |
| Description | Bexarotene is a retinoid, a member of benzoic acids and a member of naphthalenes. It has a role as an antineoplastic agent. |
| Classification | Small molecule |
| Drug class | arotinoid derivatives |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | C=C(c1ccc(C(=O)O)cc1)c1cc2c(cc1C)C(C)(C)CCC2(C)C |
Identifiers
| PDB | 3H0A |
| CAS-ID | 153559-49-0 |
| RxCUI | 233272 |
| ChEMBL ID | CHEMBL1023 |
| ChEBI ID | 50859 |
| PubChem CID | 82146 |
| DrugBank | DB00307 |
| UNII ID | A61RXM4375 (ChemIDplus, GSRS) |
Target
Agency Approved
RXRA
RXRA
RXRG
RXRG
RXRB
RXRB
Organism
Homo sapiens
Gene name
RXRA
Gene synonyms
NR2B1
NCBI Gene ID
Protein name
retinoic acid receptor RXR-alpha
Protein synonyms
Nuclear receptor subfamily 2 group B member 1, retinoid X nuclear receptor alpha, Retinoid X receptor alpha
Uniprot ID
Mouse ortholog
Rxra (20181)
retinoic acid receptor RXR-alpha (P28700)
Alternate
PPARG
PPARG
Organism
Homo sapiens
Gene name
PPARG
Gene synonyms
NR1C3
NCBI Gene ID
Protein name
peroxisome proliferator-activated receptor gamma
Protein synonyms
Nuclear receptor subfamily 1 group C member 3, peroxisome proliferator-activated receptor-gamma 5, peroxisome proliferator-activated receptor-gamma splicing, PPAR-gamma
Uniprot ID
Mouse ortholog
Pparg (19016)
peroxisome proliferator-activated receptor gamma (P37238)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,917 documents
View more details
Safety
Black-box Warning
Black-box warning for: Bexarotene, Targretin
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more